Skip to main content

Table 4 Number of Ellen genes associated with different biological pathways

From: The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures

 

Low Risk of Metastasis Genes

High Risk of Metastasis Genes

Total

Gene Expression

13

2

15

 

EGR1, FOS, JUN, NAT10, RPL11, ZFP36, EEF2, LITAF, POLR2E, POLR3E, RPLP2, RPS15, RPS23

RPL38, RPS11

 

Proliferation

5

6

11

 

KIDINS220, PIK3R1, ZFP36L2, CDIPT, CXCL12

JTB, SERPINB3, NUCKS1, SNRPE, SPDEF, TXN

 

Immune Response

5

3

8

 

FOS, CXCL12, HLA-DPA1, JAK1, PCBP2

FKBP4, MTDH, NUCKS1

 

Cell Migration

3

4

7

 

SPTBN1, CYFIP1, CXCL12

S100P, ARF6, CSTA, NUCKS1

 

Apoptosis

6

1

7

 

JUN, SGK1, LITAF, TNFRSF10B, GLTSCR2, ITM2B

S100G(-)

 

Stress Response

5

0

5

 

DUSP1, ABAT, CIRBP, GLTSCR2, GPX4

  

Metabolism

1

4

5

 

GPX4

FLOT1, SQLE, COX5B, GPR172A

 

Epigenetics

2

2

4

 

NCOR1, SMARCA2

NAT10, H3F3A

 

Angiogenesis

0

2

2

  

ACTC1, MB

 

Differentiation

2

0

2

 

DPYSL2, RAI2

  

Cell Cycle

0

1

1

  

SFN

 

PTM and Trafficking

1

0

1

 

DUSP1

  

Cytoskeleton

0

1

1

  

KRT10

Â